{"id":7008,"date":"2025-05-31T14:17:09","date_gmt":"2025-05-31T14:17:09","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solution&p=7008"},"modified":"2025-06-13T08:12:19","modified_gmt":"2025-06-13T08:12:19","slug":"celiac-disease","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/gastrointestinal-diseases\/celiac-disease\/","title":{"rendered":"Celiac Disease"},"content":{"rendered":"
\n \n
\n
\n
\n
\n

Biomarkers for celiac disease (CeD)<\/h2>\n \n\n <\/div>\n
\n

Celiac disease leads to inflammation and damage to the intestinal lining upon interaction with immunogenic gluten peptides, impacting tissue architecture and therefore directly altering the extracellular matrix (ECM)<\/a>.<\/p>\n

Biomarkers of MMP-mediated collagen degradation (C3M<\/a>, C4M<\/a>, C6M<\/a>) and immune cell activity (C4G<\/a>) offer insights into epithelial integrity and the extent of tissue damage. By capturing real-time changes in tissue architecture<\/b>, these biomarkers enable a more precise assessment of disease<\/b> activity<\/b>, therapeutic response<\/b>, and pharmacodynamic effects<\/b>, optimizing drug development and supporting internal decision making.<\/p>\n <\/div>\n <\/div>\n

\n \n Visit out gastrointestinal portfolio \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Biomarkers for monitoring disease activity and tissue integrity in CeD<\/h2>\n \n\n <\/div>\n
\n

Biomarkers of MMP-mediated collagen degradation (C3M<\/a>, C4M<\/a>, C6M<\/a>), immune cell activity (C4G<\/a>), and formation of type VII collagen (PRO-C7<\/a>) reflect histological inflammation as assess by the Q-Marsh score.<\/p>\n

These ECM biomarkers reflecting collagen remodeling and epithelial integrity offer a direct, non-invasive measure of tissue damage, complementing traditional symptom-based assessments and histology in CeD.<\/p>\n <\/div>\n <\/div>\n

\n \n Order celiac disease biomarkers \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Biomarkers for monitoring intestinal barrier integrity<\/h2>\n \n\n <\/div>\n
\n

Biomarkers of MMP-mediated collagen degradation (C3M<\/a>, C4M<\/a>, C6M<\/a>), immune cell activity (C4G<\/a>), and formation of type VII collagen (PRO-C7<\/a>) correlate inversely with villus height, directly linking biomarker levels to changes in tissue architecture and intestinal barrier integrity.<\/p>\n

This highlights their potential to go beyond traditional biomarkers of inflammation by providing a direct assessment of structural tissue damage. By integrating these biomarkers into clinical research, they can support drug development by enabling more precise evaluation of disease progression, and treatment efficacy, supporting clinical trial design and therapeutic decision-making.<\/p>\n <\/div>\n <\/div>\n <\/article>\n

\n \"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n \n <\/div>\n
\n <\/div>\n \n \n
\n
\n\n \n Interested to learn more? Reach out! \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/article>\n <\/div>\n <\/section>\n\n\n
\n \n
\n
\n
\n
\n

Biomarkers for evaluating pharmacodynamic response<\/h2>\n \n\n <\/div>\n
\n

Biomarkers of MMP-mediated collagen degradation (C3M<\/a>, C4M<\/a>, C6M<\/a>), immune cell activity (C4G<\/a>), and formation of type VII collagen (PRO-C7<\/a>) provide assessment of pharmacodynamic response to targeted therapies in CeD.<\/p>\n

A decline in biomarker levels across both treatment arms, compared to an increase in the placebo group, reflects treatment-induced changes in intestinal tissue remodeling. This demonstrates the potential of these biomarkers for supporting pharmacodynamic evaluation and advancing the development of novel therapeutics for CeD.<\/p>\n <\/div>\n <\/div>\n

\n \n Order celiac disease biomarkers \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n
\n
\n

About celiac disease<\/h2>\n \n <\/div>\n